Australia - engleză - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - voriconazole, quantity: 50 mg - tablet, film coated - excipient ingredients: povidone; croscarmellose sodium; lactose monohydrate; magnesium stearate; pregelatinised maize starch; titanium dioxide; hypromellose; triacetin - voriconazole sandoz is indicated for treatment of the following fungal infections:,- invasive aspergillosis.,- serious candida infections (including c. krusei), including oesophageal and systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia).,- serious fungal infections caused by scedosporium spp and fusarium spp.,- other serious fungal infections, in patients intolerant of, or refractory to, other therapy,- prophylaxis in patients who are at high risk of developing invasive fungal infections. the indication is based on studies including patients undergoing haematopoietic stem cell transplantation.,- this brand is only available as tablets and therefore only indicated for adults and children 12 years or older who can tolerate tablets. for dosing requirements for populations who require intravenous or oral suspension treatment see dosage and administration.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - voriconazole, quantity: 200 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; lactose monohydrate; povidone; croscarmellose sodium; magnesium stearate; titanium dioxide; hypromellose; triacetin - voriconazole sandoz is indicated for treatment of the following fungal infections:,- invasive aspergillosis.,- serious candida infections (including c. krusei), including oesophageal and systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia).,- serious fungal infections caused by scedosporium spp and fusarium spp.,- other serious fungal infections, in patients intolerant of, or refractory to, other therapy,- prophylaxis in patients who are at high risk of developing invasive fungal infections. the indication is based on studies including patients undergoing haematopoietic stem cell transplantation.,- this brand is only available as tablets and therefore only indicated for adults and children 12 years or older who can tolerate tablets. for dosing requirements for populations who require intravenous or oral suspension treatment see dosage and administration.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - voriconazole, quantity: 200 mg - tablet, film coated - excipient ingredients: lactose monohydrate; croscarmellose sodium; pregelatinised maize starch; povidone; magnesium stearate; titanium dioxide; hypromellose; triacetin - vttack is indicated for treatment of the following fungal infections: invasive aspergillosis. serious candida infections (including c. krusei), including oesophageal and systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia). serious fungal infections caused by scedosporium spp and fusarium spp. other serious fungal infections, in patients intolerant of, or refractory to, other therapy. prophylaxis in patients who are at high risk of developing invasive fungal infections. the indication is based on studies including patients undergoing haematopoietic stem cell transplantation. this brand is only available as tablets and therefore only indicated for adults and children 12 years or older who can tolerate tablets. for dosing requirements for populations who require intravenous or oral suspension treatment see dosage and administration

Australia - engleză - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - voriconazole, quantity: 50 mg - tablet, film coated - excipient ingredients: lactose monohydrate; croscarmellose sodium; pregelatinised maize starch; povidone; magnesium stearate; titanium dioxide; hypromellose; triacetin - vttack is indicated for treatment of the following fungal infections: invasive aspergillosis. serious candida infections (including c. krusei), including oesophageal and systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia). serious fungal infections caused by scedosporium spp and fusarium spp. other serious fungal infections, in patients intolerant of, or refractory to, other therapy. prophylaxis in patients who are at high risk of developing invasive fungal infections. the indication is based on studies including patients undergoing haematopoietic stem cell transplantation. this brand is only available as tablets and therefore only indicated for adults and children 12 years or older who can tolerate tablets. for dosing requirements for populations who require intravenous or oral suspension treatment see dosage and administration

Australia - engleză - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - capecitabine, quantity: 500 mg - tablet, film coated - excipient ingredients: titanium dioxide; iron oxide red; lactose monohydrate; magnesium stearate; hypromellose; microcrystalline cellulose; purified talc; croscarmellose sodium - colon cancer,capecitabine sandoz is indicated for the adjuvant treatment of patients with dukes' stage c and high-risk stage b, colon cancer, either as monotherapy or in combination with oxaliplatin.,colorectal cancer,capecitabine sandoz is indicated for the treatment of patients with advanced or metastatic colorectal cancer.,oesophagogastric cancer,capecitabine sandoz is indicated for the first-line treatment of patients with advanced oesophagogastric cancer in combination with a platinum-based regimen.,breast cancer,capecitabine sandoz is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen unless therapy with these and other standard agents are clinically contraindicated.,capecitabine sandoz in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - capecitabine, quantity: 150 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; hypromellose; croscarmellose sodium; titanium dioxide; purified talc; magnesium stearate; iron oxide red - colon cancer,capecitabine sandoz is indicated for the adjuvant treatment of patients with dukes' stage c and high-risk stage b, colon cancer, either as monotherapy or in combination with oxaliplatin.,colorectal cancer,capecitabine sandoz is indicated for the treatment of patients with advanced or metastatic colorectal cancer.,oesophagogastric cancer,capecitabine sandoz is indicated for the first-line treatment of patients with advanced oesophagogastric cancer in combination with a platinum-based regimen.,breast cancer,capecitabine sandoz is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen unless therapy with these and other standard agents are clinically contraindicated.,capecitabine sandoz in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - capecitabine, quantity: 150 mg - tablet, film coated - excipient ingredients: hypromellose; magnesium stearate; iron oxide yellow; microcrystalline cellulose; lactose; purified talc; titanium dioxide; iron oxide red; croscarmellose sodium; purified water - colon cancer:,capecitabine is indicated for the adjuvant treatment of patients with duke?s stage c and highrisk stage b, colon cancer, either as monotherapy or in combination with oxaliplatin.,colorectal cancer:,capecitabine is indicated for the treatment of patients with advanced or metastatic colorectal cancer.,oesophagogastric cancer:,capecitabine is indicated for the first-line treatment of patients with advanced oesophagogastric cancer in combination with a platinum-based regimen.,breast cancer:,capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen unless therapy with these and other standard agents are clinically contraindicated.,capecitabine in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - bisoprolol fumarate, quantity: 10 mg - tablet, film coated - excipient ingredients: calcium hydrogen phosphate; colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; pregelatinised maize starch; croscarmellose sodium; iron oxide yellow; iron oxide red; titanium dioxide; lactose monohydrate; hypromellose; macrogol 4000 - treatment of stable chronic moderate to severe heart failure in addition to ace inhibitors, and diuretics, and optionally cardiac glycosides.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - bisoprolol fumarate, quantity: 5 mg - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; croscarmellose sodium; iron oxide yellow; calcium hydrogen phosphate; colloidal anhydrous silica; pregelatinised maize starch; titanium dioxide; lactose monohydrate; hypromellose; macrogol 4000 - treatment of stable chronic moderate to severe heart failure in addition to ace inhibitors, and diuretics, and optionally cardiac glycosides.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - bisoprolol fumarate, quantity: 2.5 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; pregelatinised maize starch; microcrystalline cellulose; calcium hydrogen phosphate; colloidal anhydrous silica; magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; macrogol 4000 - treatment of stable chronic moderate to severe heart failure in addition to ace inhibitors, and diuretics, and optionally cardiac glycosides.